Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
1(8%)
Results Posted
33%(4 trials)

Phase Distribution

Ph not_applicable
3
23%
Ph phase_4
1
8%
Ph phase_1
7
54%

Phase Distribution

7

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(12)

Detailed Status

Completed12
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (63.6%)
Phase 41 (9.1%)
N/A3 (27.3%)

Trials by Status

completed1292%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 13
recruiting

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

NCT05205291
completedphase_1

Lipopolysaccharide (LPS) Challenge in Depression

NCT03142919
completedphase_1

Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal

NCT05751837
completedphase_1

Imaging the Neuroimmune System in PTSD

NCT04236986
completedphase_1

Neuroimmune Response to Lipopolysaccharide

NCT04233593
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05205291

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

Recruiting
NCT03142919Phase 1

Lipopolysaccharide (LPS) Challenge in Depression

Completed
NCT05751837Phase 1

Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal

Completed
NCT04236986Phase 1

Imaging the Neuroimmune System in PTSD

Completed
NCT04233593Phase 1

Neuroimmune Response to Lipopolysaccharide

Completed
NCT03779360Not Applicable

Intradermal LPS and Antibiotics

Completed
NCT02876601Phase 4

Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

Completed
NCT03306589Phase 1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed
NCT03551080Not Applicable

Inflammation and Brain Function - Pilot Study

Completed
NCT01978158Phase 1

Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α

Completed
NCT02211170Phase 1

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Completed
NCT01835457Not Applicable

Concentration/Meditation Limits Inflammation

Completed
NCT01352871

The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13